BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company's commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
  • TickerBMRN
  • ISINUS09061G1013
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Wedbush Research

Wedbush Morning Call - Apr 01 2020 6:58AM

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Test Of The Lows Coming? Equities remain in rally mode after the S&P 500 was able to break above the steep downtrend that we highlighted last week. In our 3/24/20 Compass we noted the potential for a snap-back rally and that a break above this downtrend, specifically above 2,350-2,370, would help give us confidence that an initial/primary low has been made. This is exactly what transpired intraday on 3/24. Now that the initial/primary low has been established and with the S&P 500 roughly 20% off the lows, we believe it is time to map out potential areas where this rally could run into resista...

Wedbush Research

Wedbush Morning Call - Mar 29 2020 5:56PM

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Bullish Outlook Intact Amid rising Middle East tensions, investors have moved to safe-havens including Treasuries and gold, all while having a muted effect on the US equity market. At this point in time, the rising tensions have done virtually no damage to the bullish trends and indicators that continue to dominate the market. We remain bullish. • 10-Year Treasury. The 10-year yield has fallen to logical support at the uptrend or 1.75%, a level we expect to hold. A breakdown would raise concerns of a deeper pullback for US equities... see chart below. • Gold Testing Key Resistance. Gold pri...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

MSCI ACWI, STOXX 600 Breaking Out The market continues to feed off of optimism surrounding the US-China “phase one” trade deal. Boris Johnson's UK election victory has added an additional tailwind, particularly in the UK and Europe, where the UK's FTSE 250 and the STOXX Europe 600 indexes are breaking out to all-time highs. At some point the euphoria is likely to wear off, but with continued global bullish developments, it remains our belief that pullbacks should be bought and that global equities are in the early stages of a broad-based advance. • Sector Relative Strength Rankings (RSR) & W...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weighte...

Wedbush Research

Wedbush Morning Call - Apr 01 2020 6:58AM

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Test Of The Lows Coming? Equities remain in rally mode after the S&P 500 was able to break above the steep downtrend that we highlighted last week. In our 3/24/20 Compass we noted the potential for a snap-back rally and that a break above this downtrend, specifically above 2,350-2,370, would help give us confidence that an initial/primary low has been made. This is exactly what transpired intraday on 3/24. Now that the initial/primary low has been established and with the S&P 500 roughly 20% off the lows, we believe it is time to map out potential areas where this rally could run into resista...

Wedbush Research

Wedbush Morning Call - Mar 29 2020 5:56PM

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch